13 / 34
Page 50
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
16
th
EuroSciCon Conference on
Immunology
M a r c h 1 1 - 1 2 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Immunology 2019
I
n this study, we investigated the effect of Nobiletin (NOB) on Toll-like receptor-9 (TLR9) signaling pathway and to highlight
the potential for developing a treatment for this pathway that plays an important role in prostate cancer. We investigated the
effects of NOB on TLR9 in LNCaP, PC-3 as prostate cancer cells and HUVEC as a control cell. Oligodinucleotide (ODN) was used
for TLR9 stimulation. Cell viability was analyzed with the WST-1 assay. TLR9 gene expression was examined by Quantitative
Reverse Transcription Polymerase Chain Reaction (qPCR). Cytokines (INF-α and INF-β) were analyzed with Enzyme-Linked
Immunosorbent Assay (ELISA). Gelatinase activity and protein expression were examined by zymography and western blotting,
respectively. Inhibitory concentrations (IC50) of NOB were found 20 µM for LNCaP and 40 µM for PC-3 and HUVEC. It was
observed that NOB increased TLR4 gene expression in PC-3 but decreased in LNCaP and HUVEC. NOB reduced the amount of
INF-α and INF-β in PC-3. It was found that NOB reduced TLR9 protein levels in PC-3 and increased IRF-7 protein levels in PC-3
and LNCaP. Gelatinase activity of MMP-9 and MMP-2 was found low in PC-3 although there was high MMP-2 activity in LNCaP
and MMP-9 activity was not observed in HUVEC. In conclusion, the effect of NOB is AR-dependent and shows a reducing effect
on TLR9 signalling pathway. NOB may be effective on prostate cancer via TLRs and also TLR9-mediated signalling pathway with
great potential may be important for new therapeutic approaches in prostate cancers.
asumandeveci@gmail.comInvestigation of the effects of Nobiletin through
Toll-like receptor-9 signalling pathway in
prostate cancer
A Deveci Ozkan1, S Kaleli
1
, H I Onen
2
, A Kalaycı Yigin
3
, Hümey-
ra Kaleli
4
and Mehmet Akdoğan
1
1
University of Sakarya, Turkey
2
University of Gazi, Turkey
3
University of Istanbul, Turkey
4
University of Sabancı, Turkey
J Clin Immunol Allergy 2019, Volume:5
DOI: 10.21767/2471-304X-C1-009